Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 13 clinical trials
None
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

develop individualized treatment options for future patients with TNF driven Focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD).

focal segmental glomerulosclerosis
steroid treatment
angiotensin converting enzyme
enzyme inhibitor
minimal change disease
  • 12 views
  • 11 Aug, 2021
  • 4 locations
None
UrApp for Childhood Nephrotic Syndrome Management (Incident Cohort)

Idiopathic nephrotic syndrome is one of the most common chronic kidney diseases in children. Patients suffer from frequent disease relapses and complications. Self-management is difficult for families and nonadherence is common, with adverse effects on the children's health. UrApp is a mobile application designed to assist families with nephrotic syndrome …

  • 0 views
  • 30 Jun, 2021
  • 3 locations
None
RItuximab From the FIRst Episode of Idiopathic Nephrotic Syndrome

Minimal change nephrotic syndrome (MCNS) is an acquired glomerular disease characterized by massive proteinuria occurring in the absence of glomerular inflammatory lesions or immunoglobulin deposits. MCNS represents a frequent cause of nephrotic syndrome (NS) in adults (10% to 25% of cases). The disease typically takes a chronic course characterized by …

  • 0 views
  • 19 Jul, 2021
  • 1 location
None
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy Focal Segmental Glomerulosclerosis and Treatment-Resistant Minimal Change Disease

treatment-resistant minimal change disease (TR-MCD).

focal segmental glomerulosclerosis
diabetic nephropathy
angiotensin converting enzyme
hba1c
glomerulosclerosis
  • 69 views
  • 30 Sep, 2021
  • 58 locations
None
Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy

Traditionally MCN is treated with a high dose of prednisolone, which induces remission in 60-90% of patients. Prednisolone treatment contains numerous side effects and the current dose is empiric. Given the lack of efficacy evidence and the risk associated with the currently accepted treatment regimen there is a need to …

vitamin d
nephropathy
active vitamin d
remission
prednisolone
  • 18 views
  • 04 Apr, 2021
  • 2 locations
None
Effect of Daily Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on Proteinuria in Pediatric Patients With Idiopathic Nephrotic Syndrome

This study evaluates the impact of transcutaneous auricular Vagus Nerve stimulation (taVNS) therapy on the incidence of nephrotic syndrome relapses in children with idiopathic nephrotic syndrome. Participants will perform taVNS 5 minutes a day for 6 months total, monitoring for signs of nephrotic syndrome relapse with both labwork and clinical …

  • 0 views
  • 06 Sep, 2021
  • 1 location
None
Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome

change disease or focal segmental glomerulosclerosis unresponsive to 8 weeks of high dose prednisone . patients either receive 2 doses of Rituximab 375 mg/m2 iv at time 0 and 14 days with

rituximab
minimal change disease
total protein
prednisone 1 mg
corticosteroids
  • 52 views
  • 22 Jan, 2021
  • 1 location
None
An Open-Label Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases

This is an open-label Phase 2 study evaluating the long term safety and tolerability of GFB-887 in patients with focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change

focal segmental glomerulosclerosis
proteinuria
segmental glomerulosclerosis
minimal change disease
glomerulosclerosis
  • 0 views
  • 23 Sep, 2021
  • 8 locations
None
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and assess changes in proteinuria after once-daily dosing over the 108-week treatment period.

glomerular filtration rate
kidney biopsy
proteinuria
mammogram
total protein
  • 0 views
  • 06 Oct, 2021
  • 2 locations
None
Nephrotic Syndrome Study Network

Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for

nephropathy
minimal change disease
total protein
kidney biopsy
nephrotic syndrome
  • 335 views
  • 26 Jan, 2021
  • 35 locations